Table 1.
Group | ||||
---|---|---|---|---|
Overall (n = 44) |
Conventional (n = 21) |
Mini-Flap (n = 23) |
p-Value | |
Age, years | 40.07 ± 12.01 | 41.19 ± 12.04 | 39.04 ± 12.33 | 0.721 |
Sex | 1.000 | |||
Male | 5 (11.4%) | 2 (9.5%) | 3 (13.0%) | |
Female | 39 (88.6%) | 19 (90.5%) | 20 (87.0%) | |
BMI (kg/m2) | 24.11 ± 4.22 | 24.07 ± 2.88 | 24.15 ± 5.23 | 0.951 |
Extent of surgery | 1.000 | |||
Total thyroidectomy | 7 (15.9%) | 3 (14.3%) | 4 (17.4%) | |
Unilateral thyroidectomy | 37 (84.1%) | 18 (85.7%) | 19 (82.6%) | |
CND | 0.709 | |||
Not performed | 7 (15.9%) | 2 (9.5%) | 5 (21.7%) | |
Unilateral | 36 (81.8%) | 18 (85.7%) | 18 (78.3%) | |
Bilateral | 1 (2.3%) | 1 (4.8%) | 0 | |
Nodes retrieved | 5.60 ± 3.97 | 6.81 ± 4.39 | 4.45 ± 3.20 | 0.050 |
Metastatic LN | 1.14 ± 2.04 | 1.38 ± 2.58 | 0.91 ± 1.38 | 0.455 |
Tumor diameter (cm) | 1.05 ± 0.75 | 0.88 ± 0.60 | 1.21 ± 0.85 | 0.149 |
Pathologic diagnosis | 1.000 | |||
PTC | 34 (77.3%) | 17 (81.0%) | 17 (73.9%) | |
HCC | 1 (2.3%) | 0 | 1(4.3%) | |
Benign | 9 (20.5%) | 4 (19.0%) | 5 (21.7%) | |
ETE | 1.000 | |||
Yes | 1 (2.3%) | 0 | 1 (4.3%) | |
No | 43 (97.7%) | 21 (100.0%) | 22 (95.7%) | |
Thyroiditis | 0.042 | |||
Yes | 12 (27.3%) | 9 (42.9%) | 3 (13.0%) | |
No | 32 (72.7%) | 12 (57.1%) | 20 (87.0%) | |
Pathological T stage * | 1.000 | |||
1a | 26 (74.3%) | 13 (76.5%) | 13 (72.2%) | |
1b | 8 (22.9%) | 4 (23.5%) | 4 (22.2%) | |
3b | 1 (2.9%) | 0 | 1 (5.6%) | |
Pathological N stage * | 0.845 | |||
0 | 15 (42.9%) | 7 (41.2%) | 8 (44.4%) | |
1a | 20 (57.1%) | 10 (58.8%) | 10 (55.6%) | |
AJCC (8th edition) stage * | 1.000 | |||
I | 33 (94.3%) | 16 (94.1%) | 17 (94.4%) | |
II | 2 (5.7%) | 1 (5.9%) | 1 (5.6%) |
* Available for the 35 patients with malignancy. Values are expressed as mean ± standard deviation or numbers (%). BMI, body mass index; CND, central node dissection; PTC, papillary thyroid cancer; HCC, Hürthle cell carcinoma; ETE, extrathyroidal extension.